Thursday, June 05, 2008

Antipsychotics Market Insight and Analysis 2008

Schizophrenia is a chronic, severe, and disabling brain disease. Approximately 1% of the population develops schizophrenia during their lifetime and more than 2 million Americans suffer from the illness in a given year.

Schizophrenia is charecterized by hallucinations and delusions, as well as cognitive symptoms such as the inability to focus attention. Treatment of diminished cognition represents an unmet need in the field of schizophrenia and one that LeadDiscovery has been focussing on in UpdatesPlus-Nicotinic Receptors.

Nicotinic receptor modulators represent an exciting emmerging therapeutic class. In particular alpha7 nicotinic receptor modulators have shown promise in the treatment of Alzheimer's disease and cognitive impairment associated with schizophrenia. There are currently 8 candidates from this class in the clinic and many more in preclinical development. Today's edition of DailyUpdates-Psychiatric Diseases focuses on a new candidate, Pfizer's PHA-709829. Acker and colleagues report that this compound shows potent and selective alpha7 in vitro activity, excellent brain penetration, good rat oral bioavailability and robust in vivo efficacy in a rat auditory sensory gating model. Further analysis of this paper will appear in the next edition of UpdatesPlus.

Today's edition of DailyUpdates also features a new reports on the more well known aspect of schizophrenia, psychosis. The report Antipsychotics Market Insight and Analysis 2008 forecasts the future antipsychotics market. Revenue from the sale of antipsychotics was $18.1 in 2006 and is expected to reach $18.6bn by 2007. But what will it be in 2012?

This in-depth market analysis examines prospects for antipsychotic drugs right through to 2012, including sales forecasts for leading products. The antipsychotics market will face decreasing growth throughout the forecast period, due to the patent expiry of leading blockbuster drugs. Safety concerns over the current antipsychotics along with high prices, will also contribute to decreased growth in this market.

The antipsychotics market currently contains four blockbuster drugs; Zyprexa, Risperdal, Seroquel and Abilify. This report predicts that a fifth drug will also reach blockbuster status by 2008. The authors also highlight pipeline developments and important contemporary issues, especially commercial drivers and restraints.

According to the National Alliance for Research on Schizophrenia and Depression, approximately 22.1 per cent of American adults (approximately 64 million people) suffer from a diagnosable mental illness in any given year. Of these, it is estimated that over 2 million suffer from schizophrenia. Similarly, approximately 18.8 million people have a depressive disorder, with approximately 2.3 to 3 million suffering from bipolar disorder.

The Antipsychotic Drugs Market Insight and Analysis 2008 examines the market critically through a comprehensive review of available information. Sources include primary research unavailable elsewhere, in-house and industrial databases, commercial news, published reports, economic research and consultation with experts. The report applies financial forecasting, qualitative analyses and the assessment of unmet needs to provide a comprehensive market report with detailed analysis and informed opinion.

In particular, The Antipsychotics Market concentrates on the following essential aspects of the market:

  • Discussion of the current pharmaceutical market
  • Forecast of the worldwide pharmaceutical market from 2007-2012
  • Drivers and restraints facing the antipsychotics market
  • Opportunities and threats facing the antipsychotics market
  • Growth of the antipsychotic drugs market between 2007-2012
  • Commercial prospects for the market-leading drugs, with sales forecasts from 2007-2012
  • The potential of generics manufacturers to penetrate this market
  • Pipeline developments with blockbuster potential
  • Currently marketed drugs with blockbuster potential
  • Discussion of unmet therapeutic needs and relative advantages of products
For similar reports visit PharmaReport - Psychiatric, Addictive & Sleep Disorders